Eli Lilly Gains on Q4 Beat, 43% Growth and Oral GLP-1 Filing Plan
Eli Lilly shares rose in Q4 2025 on easing U.S. drug pricing uncertainty and a late-October earnings beat, while its obesity pipeline gained momentum with a planned year-end oral GLP-1 submission. Revenue grew 45% to $65.2 billion with 43% Q4 growth; hedge fund ownership rose from 114 to 137.
1. Q4 Performance Drivers
Eli Lilly shares were buoyed by reduced U.S. drug pricing uncertainty following updated policy guidance, a late-October earnings beat with a raised outlook, and accelerated momentum from its obesity pipeline highlighted by plans to submit an oral GLP-1 obesity treatment for global approval by year-end.
2. Financial Results
Full-year 2025 revenue advanced 45% to $65.2 billion, with fourth-quarter sales rising 43%, driven by strong demand for its incretin portfolio in obesity and diabetes and positive Phase 2 data for next-generation incretin candidate eloralintide.
3. Hedge Fund Interest
Hedge fund holdings climbed to 137 portfolios from 114 the previous quarter, reflecting growing investor confidence in Lilly’s durable cash generation, robust pipeline execution and long-term growth prospects.